91 results on '"R, Rivera Díaz"'
Search Results
2. Implementación de las recomendaciones sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto, la lactancia y el cuidado perinatal en pacientes con psoriasis
- Author
-
I. Belinchón, S. Armesto, P. de la Cueva, L. Ferrándiz, R. Rivera Díaz, and J.M. Carrascosa
- Subjects
Psoriasis ,Fertility ,Pregnancy ,Postpartum ,Breastfeeding ,Recommendations ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Resumen: Objetivo: Analizar el grado de implementación de las recomendaciones del Grupo de Psoriasis (GPS) sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto, la lactancia y el cuidado perinatal en la psoriasis. Métodos: Se diseñó y envió una encuesta cerrada, estructurada y anónima, en formato electrónico a miembros del GPS a través del correo electrónico. Se recogieron las variables sociodemográficas y profesionales de los participantes, y otras relacionadas con los objetivos propuestos. Se realizó un análisis descriptivo. Resultados: Se analizaron 53 encuestas. El 96% de los participantes conocen las recomendaciones del GPS, pero su nivel de participación en unidades de atención multidisciplinar o la disposición de protocolos específicos en los servicios es muy baja. El 70% pregunta de forma regular sobre el deseo gestacional, aunque solo el 46% lo pregunta a varones y mujeres. Se ofrece consejo preconcepcional más a mujeres que a varones (54 vs. 19%). Gran variabilidad en cuanto a los consejos ofrecidos. El 90% suspende tratamientos tópicos durante el embarazo, y prácticamente el 100% los tratamientos sistémicos salvo la ciclosporina A. En el tercer trimestre se suspenden la mayoría de las terapias biológicas a excepción de certolizumab pegol. Los tratamientos tópicos, fototerapia y certolizumab pegol son usados casi por el 100% de los encuestados en la lactancia. La falta de tiempo, de apoyo de los gestores y de datos robustos son las principales limitaciones a la implementación de las recomendaciones. Conclusiones: A pesar de que son ampliamente conocidas, las recomendaciones del GPS aún quedan áreas de mejora. Abstract: Objective: To analyze degree of implementation of recommendations on the management of psoriasis during preconception, pregnancy, postpartum, breastfeeding, and perinatal care published by the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). Methods: We designed a structured online survey consisting of closed questions. A link was emailed to all the members of the Psoriasis Working Group to collect their anonymous responses. We also collected sociodemographic, professional, and practice-related data related to the goals of the study and then compiled descriptive statistics to analyze the survey findings. Results: We received 53 responses for analysis. Overall, 96% of respondents were familiar with the recommendations, but very few of them worked in multidisciplinary maternity care units or had access to specific protocols on the management of psoriasis before, during, and after pregnancy in their departments. Seventy percent of dermatologists regularly ask their patients about pregnancy plans, but only 46% ask both men and women. Women also receive more preconception advice than men (54% vs. 19%). Significant variations were observed in the type of advice given. Ninety percent of the dermatologists interrupt topical treatments during pregnancy, and nearly all suspend conventional systemic drugs with the exception of cyclosporin A. Most biologics are also being discontinued in the third trimester, with the exception of certolizumab pegol. Almost all the respondents indicated that they use topical treatments, phototherapy, and certolizumab pegol in breastfeeding mothers. The main barriers to implementing the working group's recommendations are a lack of time, a lack of support, and a lack of robust data. Conclusions: Although the AEDV psoriasis working group's recommendations are widely known, areas for improvement remain.
- Published
- 2022
- Full Text
- View/download PDF
3. [Artículo traducido] Los inhibidores selectivos de la IL23 son, en su mayoría, efectivos y seguros en pacientes con psoriasis y fallo previo a tratamientos biológicos anti IL-17. Una experiencia de práctica clínica real a 52 semanas
- Author
-
J. Arroyo-Andrés, D. Falkenhain-López, M. Agud-Dios, and R. Rivera-Díaz
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2023
- Full Text
- View/download PDF
4. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM
- Author
-
L.M. Nieto Benito, G. Carretero, R. Rivera-Díaz, J.M. Carrascosa, E. Daudén, P. de la Cueva, A. Sahuquillo-Torralba, E. Herrera-Acosta, O. Baniandrés-Rodríguez, J.L. Lopez-Estebaranz, I. Belinchón, J. Riera-Monroig, M. Ferrán, F.J. Gómez-García, A. Mateu, L. Rodríguez, J. Vilar-Alejo, C. García-Donoso, F. Ballescá, Llamas-M. Velasco, R. Botella-Estrada, E. Herrera-Ceballos, D.P. Ruiz-Genao, M.A. Descalzo, and I. García-Doval
- Subjects
BIOBADADERM ,Childhood ,Psoriasis ,Registries ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Resumen: El comienzo de la psoriasis en la edad pediátrica, aunque generalmente leve, puede requerir tratamiento sistémico en las formas moderadas o graves de la enfermedad. El objetivo de este trabajo es analizar la frecuencia relativa, las características de los pacientes, el tratamiento empleado y los eventos adversos (EA) observados a partir del registro BIOBADADERM en niños y jóvenes con psoriasis moderada-grave. Del total de 3.946 pacientes del registro, se incluyen 24 pacientes menores de 21 años, con una edad media al inicio del tratamiento en BIOBADADERM de 16,1 años y un PASI medio de 9,4. El 67% de los pacientes estaba en tratamiento sistémico clásico al inicio del registro. Catorce pacientes (58%) suspendieron el tratamiento por pérdida o falta de eficacia o por EA. En conclusión, los datos del registro BIOBADADERM muestran que los menores representan un grupo muy pequeño dentro de los pacientes con psoriasis que reciben tratamiento sistémico y son manejados más frecuentemente con tratamientos clásicos. Abstract: Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. They had mean age of 16.1 years on starting treatment. When the registry was started, they had a Psoriasis Area and Severity Index of 9.4 and 67% were being treated with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs.
- Published
- 2022
- Full Text
- View/download PDF
5. Condilomas acuminados resistentes a los tratamientos convencionales con buena respuesta a tratamiento con terapia fotodinámica
- Author
-
B. Pinilla Martín, R. Rivera Díaz, and V. Monsálvez Honrubia
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2022
- Full Text
- View/download PDF
6. [Translated article] Implementation of Recommendations for the Management of Psoriasis During Preconception, Pregnancy, Postpartum, Breastfeeding, and Perinatal Care
- Author
-
I. Belinchón, S. Armesto, P. de la Cueva, L. Ferrándiz, R. Rivera Díaz, and J.M. Carrascosa
- Subjects
Psoriasis ,Fertilidad ,Embarazo ,Posparto ,Lactancia ,Recomendaciones ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Objective: To analyze degree of implementation of recommendations on the management of psoriasis during preconception, pregnancy, postpartum, breastfeeding, and perinatal care published by the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). Methods: We designed a structured online survey consisting of closed questions. A link was emailed to all the members of the Psoriasis Working Group to collect their anonymous responses. We also collected sociodemographic, professional, and practice-related data related to the goals of the study and then compiled descriptive statistics to analyze the survey findings. Results: We received 53 responses for analysis. Overall, 96% of respondents were familiar with the recommendations, but very few of them worked in multidisciplinary maternity care units or had access to specific protocols on the management of psoriasis before, during, and after pregnancy in their departments. Seventy percent of dermatologists regularly ask their patients about pregnancy plans, but only 46% ask both men and women. Women also receive more preconception advice than men (54% vs. 19%). Significant variations were observed in the type of advice given. Ninety percent of the dermatologists interrupt topical treatments during pregnancy, and nearly all suspend conventional systemic drugs with the exception of cyclosporin A. Most biologics are also being discontinued in the third trimester, with the exception of certolizumab pegol. Almost all the respondents indicated that they use topical treatments, phototherapy, and certolizumab pegol in breastfeeding mothers. The main barriers to implementing the working group's recommendations are a lack of time, a lack of support, and a lack of robust data. Conclusions: Although the AEDV psoriasis working group's recommendations are widely known, areas for improvement remain. Resumen: Objetivo: Analizar el grado de implementación de las recomendaciones del Grupo de Psoriasis (GPS) sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto, la lactancia y el cuidado perinatal en la psoriasis. Métodos: Se diseñó y envió una encuesta cerrada, estructurada y anónima, en formato electrónico a miembros del GPS a través del correo electrónico. Se recogieron las variables sociodemográficas y profesionales de los participantes, y otras relacionadas con los objetivos propuestos. Se realizó un análisis descriptivo. Resultados: Se analizaron 53 encuestas. El 96% de los participantes conocen las recomendaciones del GPS, pero su nivel de participación en unidades de atención multidisciplinar o la disposición de protocolos específicos en los servicios es muy baja. El 70% pregunta de forma regular sobre el deseo gestacional, aunque solo el 46% lo pregunta a varones y mujeres. Se ofrece consejo preconcepcional más a mujeres que a varones (54 vs. 19%). Gran variabilidad en cuanto a los consejos ofrecidos. El 90% suspende tratamientos tópicos durante el embarazo, y prácticamente el 100% los tratamientos sistémicos salvo la ciclosporina A. En el tercer trimestre se suspenden la mayoría de las terapias biológicas a excepción de certolizumab pegol. Los tratamientos tópicos, fototerapia y certolizumab pegol son usados casi por el 100% de los encuestados en la lactancia. La falta de tiempo, de apoyo de los gestores y de datos robustos son las principales limitaciones a la implementación de las recomendaciones. Conclusiones: A pesar de que son ampliamente conocidas, las recomendaciones del GPS aún quedan áreas de mejora.
- Published
- 2022
- Full Text
- View/download PDF
7. Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis
- Author
-
I. Belinchón, M. Velasco, M. Ara-Martín, S. Armesto Alonso, O. Baniandrés Rodríguez, L. Ferrándiz Pulido, M. García-Bustinduy, J.A. Martínez-López, N. Martínez Sánchez, A. Pérez Ferriols, E. Pérez Pascual, R. Rivera Díaz, R. Ruiz-Villaverde, R. Taberner Ferrer, A. Vicente Villa, and J.M. Carrascosa
- Subjects
Psoriasis ,Fertility ,Pregnancy ,Postpartum ,Breastfeeding ,Delphi process ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Resumen: Objetivo: Desarrollar recomendaciones basadas en la mejor evidencia y experiencia sobre el manejo de pacientes con psoriasis durante la edad fértil, el embarazo, el posparto y la lactancia. Métodos: Se siguió la metodología de grupos nominales y Delphi. Se seleccionó un grupo director de expertos (12 dermatólogos —de los cuales 2 fueron los coordinadores—, 1 reumatólogo, 2 ginecólogos). Se realizó una revisión sistemática de la literatura sobre fertilidad, embarazo, posparto y lactancia en pacientes con psoriasis. Con esta información los coordinadores generaron una serie de recomendaciones preliminares. Todo ello se presentó y discutió con el resto de expertos en una reunión de grupo nominal donde se definió el alcance, los usuarios, los apartados del documento, y donde se generaron las recomendaciones definitivas. El grado de acuerdo con las recomendaciones se votó siguiendo la metodología Delphi, que se extendió a 51 dermatólogos más, según una escala de 1 (total desacuerdo) a 10 (total acuerdo), definiéndose el acuerdo como una puntuación ≥ 7 por al menos el 70% de los participantes. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford. El documento completo final fue aprobado por el panel de expertos. Resultados: Se generaron 23 recomendaciones sobre el periodo pre-concepcional (fertilidad y anticoncepción), el embarazo (planificación, manejo farmacológico y seguimiento) y la lactancia (manejo y seguimiento). Todas las recomendaciones menos una alcanzaron el nivel de acuerdo definido. Conclusiones: En los pacientes con psoriasis en edad fértil estas recomendaciones pueden mejorar el manejo, los resultados y el pronóstico. Abstract: Objective: To develop evidence- and experience-based recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. Methods: The nominal group technique and the Delphi method were used. Fifteen experts (12 dermatologists, 2 of whom were appointed coordinators; 1 rheumatologist; and 2 gynecologists) were selected to form an expert panel. Following a systematic review of the literature on fertility, pregnancy, postpartum, and breastfeeding in women with psoriasis, the coordinators drew up a series of preliminary recommendations for discussion by the panel at a nominal group meeting. The experts defined the scope, sections, and intended users of the statement and prepared a final list of recommendations. Consensus was obtained using a Delphi process in which an additional 51 dermatologists rated their level of agreement with each recommendation on a scale of 1 (total disagreement) to 10 (total agreement). Consensus was defined by a score of 7 or higher assigned by at least 70% of participants. Level of evidence and strength of recommendation were reported using the Oxford Center for Evidence-Based Medicine categories. The final statement was approved by the expert panel. Results: The resulting consensus statement includes 23 recommendations on preconception (fertility and contraception), pregnancy (planning, pharmacological management, and follow-up), and breastfeeding (management and follow-up). Consensus was achieved for all recommendations generated except one. Conclusions: These recommendations for the better management of psoriasis in women of childbearing age could improve outcomes and prognosis.
- Published
- 2021
- Full Text
- View/download PDF
8. [Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
- Author
-
L.M. Nieto Benito, G. Carretero, R. Rivera-Díaz, J.M. Carrascosa, E. Daudén, P. de la Cueva, A. Sahuquillo-Torralba, E. Herrera-Acosta, O. Baniandrés-Rodríguez, J.L. Lopez-Estebaranz, I. Belinchón, J. Riera-Monroig, M. Ferrán, F.J. Gómez-García, A. Mateu, L. Rodríguez, J. Vilar-Alejo, C. García-Donoso, F. Ballescá, L.-M. Velasco, R. Botella-Estrada, E. Herrera-Ceballos, D.P. Ruiz-Genao, M.A. Descalzo, and I. García-Doval
- Subjects
BIOBADADERM ,Infancia ,Psoriasis ,Registros ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs. Resumen: El comienzo de la psoriasis en la edad pediátrica, aunque generalmente leve, puede requerir tratamiento sistémico en las formas moderadas o graves de la enfermedad. El objetivo de este trabajo es analizar la frecuencia relativa, las características de los pacientes, el tratamiento empleado y los eventos adversos observados a partir del registro BIOBADADERM en niños y jóvenes con psoriasis moderada-grave. Del total de 3.946 pacientes del registro, se incluyen 24 pacientes menores de 21 años, con una edad media al inicio del tratamiento en BIOBADADERM de 16,1 años y un PASI medio de 9,4. El 67% de los pacientes estaban en tratamiento sistémico clásico al inicio del registro. Catorce pacientes (58%) suspendieron el tratamiento por pérdida o falta de eficacia o por eventos adversos. En conclusión, los datos del registro BIOBADADERM muestran que los menores representan un grupo muy pequeño dentro de los pacientes con psoriasis que reciben tratamiento sistémico y son manejados más frecuentemente con tratamientos clásicos.
- Published
- 2022
- Full Text
- View/download PDF
9. [Translated article] Refractory Anogenital Warts: Good Response to Photodynamic Therapy
- Author
-
B. Pinilla Martín, R. Rivera Díaz, and V. Monsálvez Honrubia
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2022
- Full Text
- View/download PDF
10. De un anti-IL-17 a otro: dar una segunda oportunidad o cambiar de diana
- Author
-
B. Pinilla Martín, A. Sánchez Velázquez, C. Vico Alonso, and R. Rivera Díaz
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2021
- Full Text
- View/download PDF
11. Medicina de precisión en psoriasis
- Author
-
R. Rivera-Díaz and I. Belinchón
- Subjects
General Medicine - Published
- 2022
12. Proyecto CUDERMA: Consenso Delphi de los indicadores de calidad para la certificación de las unidades de dermatología de atención en psoriasis
- Author
-
L. Salgado-Boquete, S. Arias-Santiago, I. Belinchón-Romero, A. de la Cuadra-Grande, P. de la Cueva, Y. Gilaberte, J. Notario, R. Rivera-Díaz, R. Ruiz-Villaverde, and J.M. Carrascosa
- Subjects
Calidad asistencial ,Delphi technique ,Quality indicator ,Unidad de Dermatología ,Quality of care ,Psoriasis ,General Medicine ,Consenso Delphi ,Dermatology Unit ,Indicador de calidad - Abstract
El proyecto ha sido impulsado y financiado por la Academia Española de Dermatología y Venereología (AEDV) con una beca sin restricciones de Abbvie., La definición de indicadores de calidad es una estrategia clave para garantizar la calidad de la asistencia sanitaria y su homogenización. Así, el proyecto CUDERMA surge como una iniciativa de la AEDV para definir indicadores de calidad con los que certificar unidades de distintos campos de interés en la dermatología, de los que se seleccionaron psoriasis y dermatooncología de forma inicial. El objetivo de este trabajo fue consensuar los aspectos a evaluar por los indicadores en la certificación de las unidades de psoriasis. Para ello se siguió un proceso estructurado que contempló la revisión bibliográfica de indicadores, la elaboración de un set preliminar revisado por un grupo de expertos multidisciplinar y el consenso Delphi. Un panel de 39 dermatólogos evaluó los indicadores, y los clasificó como «básicos» o «de excelencia». Finalmente se consensuaron 67 indicadores que serán estandarizados para dise˜nar la norma con la que certificar las unidades de psoriasis., Defining quality indicators is a key strategy for ensuring the quality and standardization of health care. The CUDERMA project, an initiative of the Spanish Academy of Dermatology and Venerology (AEDV), was undertaken to define quality indicators for the certification of specialized units in dermatology; the first 2 areas selected were psoriasis and dermato-oncology. The aim of this study was to reach a consensus on what should be assessed by the indicators used to certify psoriasis units. The structured process used to do this comprised a literature review to identify potential indicators, the selection of an initial set of indicators to be evaluated by a multidisciplinary group of experts and, finally, a Delphi consensus study. A panel of 39 dermatologists evaluated the selected indicators and classified them as either “essential” or “of excellence”. Consensus was finally reached on 67 indicators, which will be standardized and used to develop the certification standard for psoriasis units., Academia Española de Dermatología y Venereología (AEDV), AbbVie
- Published
- 2023
13. Condilomas acuminados resistentes a los tratamientos convencionales con buena respuesta a tratamiento con terapia fotodinámica
- Author
-
V. Monsálvez Honrubia, B. Pinilla Martín, and R. Rivera Díaz
- Subjects
business.industry ,Medicine ,General Medicine ,business - Published
- 2022
14. Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis
- Author
-
N. Martínez Sánchez, M. Velasco, R. Taberner Ferrer, S. Armesto Alonso, Isabel Belinchón, M. Ara-Martín, A. Pérez Ferriols, O. Baniandrés Rodríguez, José Manuel Carrascosa, Marta García-Bustínduy, Ricardo Ruiz-Villaverde, R. Rivera Díaz, L. Ferrándiz Pulido, E. Pérez Pascual, J.A. Martínez-López, and A. Vicente Villa
- Subjects
medicine.medical_specialty ,Consensus ,Histology ,Embarazo ,media_common.quotation_subject ,Breastfeeding ,Delphi method ,Posparto ,Fertility ,Dermatology ,Recommendations ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Postpartum ,Pregnancy ,Nominal group technique ,Humans ,Psoriasis ,Medicine ,Método Delphi ,media_common ,030203 arthritis & rheumatology ,Lactancia ,business.industry ,Postpartum Period ,Nominal group ,Evidence-based medicine ,medicine.disease ,Breast Feeding ,Contraception ,Fertilidad ,Scale (social sciences) ,Family medicine ,Recomendaciones ,Female ,Delphi process ,business - Abstract
Objective To develop evidence- and experience-based recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. Methods The nominal group technique and the Delphi method were used. Fifteen experts (12 dermatologists, 2 of whom were appointed coordinators; 1 rheumatologist; and 2 gynecologists) were selected to form an expert panel. Following a systematic review of the literature on fertility, pregnancy, postpartum, and breastfeeding in women with psoriasis, the coordinators drew up a series of preliminary recommendations for discussion by the panel at a nominal group meeting. The experts defined the scope, sections, and intended users of the statement and prepared a final list of recommendations. Consensus was obtained using a Delphi process in which an additional 51 dermatologists rated their level of agreement with each recommendation on a scale of 1 (total disagreement) to 10 (total agreement). Consensus was defined by a score of 7 or higher assigned by at least 70% of participants. Level of evidence and strength of recommendation were reported using the Oxford Center for Evidence-Based Medicine categories. The final statement was approved by the expert panel. Results The resulting consensus statement includes 23 recommendations on preconception (fertility and contraception), pregnancy (planning, pharmacological management, and follow-up), and breastfeeding (management and follow-up). Consensus was achieved for all recommendations generated except one. Conclusions These recommendations for the better management of psoriasis in women of childbearing age could improve outcomes and prognosis. Objetivo Desarrollar recomendaciones basadas en la mejor evidencia y experiencia sobre el manejo de pacientes con psoriasis durante la edad fértil, el embarazo, el posparto y la lactancia. Métodos Se siguió la metodología de grupos nominales y Delphi. Se seleccionó un grupo director de expertos (12 dermatólogos —de los cuales 2 fueron los coordinadores—, 1 reumatólogo, 2 ginecólogos). Se realizó una revisión sistemática de la literatura sobre fertilidad, embarazo, posparto y lactancia en pacientes con psoriasis. Con esta información los coordinadores generaron una serie de recomendaciones preliminares. Todo ello se presentó y discutió con el resto de expertos en una reunión de grupo nominal donde se definió el alcance, los usuarios, los apartados del documento, y donde se generaron las recomendaciones definitivas. El grado de acuerdo con las recomendaciones se votó siguiendo la metodología Delphi, que se extendió a 51 dermatólogos más, según una escala de 1 (total desacuerdo) a 10 (total acuerdo), definiéndose el acuerdo como una puntuación = 7 por al menos el 70% de los participantes. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford. El documento completo final fue aprobado por el panel de expertos. Resultados Se generaron 23 recomendaciones sobre el periodo pre-concepcional (fertilidad y anticoncepción), el embarazo (planificación, manejo farmacológico y seguimiento) y la lactancia (manejo y seguimiento). Todas las recomendaciones menos una alcanzaron el nivel de acuerdo definido. Conclusiones En los pacientes con psoriasis en edad fértil estas recomendaciones pueden mejorar el manejo, los resultados y el pronóstico.
- Published
- 2021
15. Mycosis fungoides: molecular identity revealed by nanostring analysis
- Author
-
R Alonso Alonso, M Rodríguez Moreno, N García Díaz, JF García García, LT Roca, J Borregón Caselles, M Cabezuelo Rodríguez, L Cereceda Company, SM Rodríguez Pinilla, R Córdoba Mascuñano, J Torre Castro, CM García Álvarez, JL Rodríguez Peralto, R Rivera Díaz, JP Vaqué Díez, PL Ortiz-Romero, and MA Piris Pinilla
- Subjects
Cancer Research ,Oncology - Published
- 2022
16. De un anti-IL-17 a otro: dar una segunda oportunidad o cambiar de diana
- Author
-
C. Vico Alonso, A. Sánchez Velázquez, B. Pinilla Martín, and R. Rivera Díaz
- Subjects
RL1-803 ,General Medicine ,Dermatology ,Internal medicine ,RC31-1245 - Published
- 2021
17. Switching From One Anti-IL-17 Antibody to Another: On Trying Again or Changing the Target
- Author
-
R. Rivera Díaz, B. Pinilla Martín, C. Vico Alonso, and A. Sánchez Velázquez
- Subjects
Histology ,biology ,business.industry ,Immunology ,biology.protein ,Medicine ,Dermatology ,Interleukin 17 ,Antibody ,business ,Pathology and Forensic Medicine - Published
- 2021
18. WITHDRAWN: Refractory Anogenital Warts: Good Response to Photodynamic Therapy
- Author
-
R. Rivera Díaz, B. Pinilla Martín, and V. Monsálvez Honrubia
- Subjects
medicine.medical_specialty ,Histology ,Refractory ,business.industry ,medicine.medical_treatment ,medicine ,Photodynamic therapy ,Dermatology ,business ,Pathology and Forensic Medicine - Published
- 2021
19. POS1075 CROSS-SECTIONAL OBSERVATIONAL AND MULTICENTER STUDY FOR THE VALIDATION OF THE SPANISH VERSION OF THE PURE-4 QUESTIONNAIRE
- Author
-
R. Queiro Silva, I. Belinchón, A. Lopez-Ferrer, M. Ferran I Farrés, R. Rivera Díaz, D. Vidal Sarro, L. Rodriguez Freire, P. De la Cueva Dobao, J. Santos Juanes, V. Rocamora Duran, C. Sanabra, G. Guinea Uzábal, and V. Martín Vázquez
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundThe Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4) has been culturally adapted to Spanish language recently following the standardized methodology.1 A group of experts in psoriasis and psoriatic arthritis (PsA) has recently recommended the use of the Spanish version of PURE-4 due to the reduced number of items, its high sensitivity and specificity and the feasibility to implement in the clinical practice.ObjectivesTo validate the Spanish version of the PURE-4 questionnaire.MethodsCross-sectional, observational and multicenter study conducted with primary data collection under conditions of routine clinical practice in Spain. The study included adult patients with diagnosis of psoriasis of any time of evolution and any type of severity, that voluntarily accepted to participate. Primary endpoint: validation of PURE-4 questionnaire in terms of sensitivity, specificity, feasibility, reliability (internal consistency) and construct validity. The study consists in two cross-sectional evaluations: assessment I (a visit performed by a dermatologist, followed by an independent visit to the rheumatologist within the following 4 weeks after to the dermatologist’s visit and scheduled according to routine clinical practice) and assessment II (patients without PsA in assessment I will be evaluated by the rheumatologist one year ±2 months later and the rheumatologist will perform the PsA diagnostic confirmation according to the rheumatologist criteria and will collect clinical characteristics). Since data from assessment II are not yet available, data from assessment I are presented.Results268 evaluable patients included, 57.1% male, with a mean (SD) age of 47.1 (12.6) years, a mean (SD) time from diagnosis of 18.6 (12.9) years and mostly receiving psoriasis treatment (88.8%), biological treatment being the most common (43.3%). Mean (SD) PURE-4 score for all patients was 1.4 (1.3), being 2.3 (1.1) for patients with PsA and 1.3 (1.3) for patients without PsA diagnosis (Table 1). 268 (100.0%) patients answered the full PURE-4 questionnaire. Area under the receiver-operating characteristic (ROC) curve was 0.7185 (95% CI: 0.6391, 0.7978), showing good quality of fit or quality of the questionnaire (Figure 1). Using the Youden index, which determines the optimal cut-off point for the classification of patients, it was identified that a score ≥2 indicated a diagnosis of PsA. PURE-4 questionnaire showed a sensitivity of 77.1% and a specificity of 61.1%.Table 1.Sociodemographic and clinical baseline characteristics (assessment I)CharacteristicsWith PsA diagnosis (n=35)Without PsA diagnosis (n=226)Not assesable (n=7)Total (n=268)Age, mean (SD)50.5 (10.0)46.5 (12.9)49.9 (11.2)47.1 (12.6)Female, n (%)14 (40.0%)97 (42.9%)4 (57.1%)115 (42.9%)Years since diagnosis, mean (SD)19.7 (14.2)18.3 (12.8)22.4 (9.0)18.6 (12.9)Current treatment for psoriasis, n (%)32 (91.4%)199 (88.1%)7 (100.0%)238 (88.8%)Phototherapy, n (%)5 (15.6%)16 (8.0%)0 (0.0%)21 (8.8%)Topic treatment, n (%)20 (62.5%)66 (33.2%)3 (42.9%)89 (37.4%)Conventional systemic no biological treatment, n (%)7 (21.9%)40 (20.1%)2 (28.6%)49 (20.6%)Biological treatment, n (%)8 (25.0%)91 (45.7%)4 (57.1%)103 (43.3%)Phosphodiesterase-4 inhibitors, n (%)0 (0.0%)8 (4.0%)0 (0.0%)8 (3.4%)Others, n (%)0 (0.0%)3 (1.5%)0 (0.0%)3 (1.3%)PASI, mean (SD)8.7 (5.5)7.0 (5.0)4.2 (3.1)7.2 (5.1)Mild (PASI11 (31.4%)95 (42.0%)5 (71.4%)111 (41.4%)Moderate/severe (PASI≥7), n (%)24 (68.6%)131 (58.0%)2 (28.6%)157 (58.6%)APs, psoriatic arthritis; PASI, Psoriasis Area and Severity Index; SD, standard deviation.Figure 1.Area under the ROC curve (assessment I)ConclusionPURE-4 is a valid and compliant questionnaire with clinical practice in dermatology. It could be answered by patients in the waiting room and reviewed by dermatologists during the visit to support decision-making. PURE-4 could also help rheumatologists to early diagnose PsA patients in clinical practice.References[1]Actas Dermosifiliogr. 2020;111(8):655-64.AcknowledgementsThe authors thank IQVIA and Carmen Barrull, Neus Canal and Marco Pinel for providing medical editorial assistance with this presentation.Disclosure of InterestsRubén Queiro Silva Speakers bureau: AbbVie, MSD, Pfizer, Novartis, Lilly, Janssen, UCB y Celgene., Consultant of: AbbVie, MSD, Pfizer, Novartis, Lilly, Janssen, UCB y Celgene., Grant/research support from: Novartis, AbbVie y Janssen., Isabel Belinchón Speakers bureau: Janssen Pharmaceuticals Inc., Almirall, Lilly, AbbVie, Novartis, Celgene, Biogen Amgen, Leo-Pharma, Pfizer-Wyeth, UCB y MSD., Consultant of: Janssen Pharmaceuticals Inc., Almirall, Lilly, AbbVie, Novartis, Celgene, Biogen Amgen, Leo-Pharma, Pfizer-Wyeth, UCB y MSD., Anna Lopez-Ferrer Speakers bureau: Novartis, Janssen, MSD, Lilly, Pfizer,Celgene, Almirall, Leo Pharma, AbbVie y Amgen., Consultant of: Novartis, Janssen, MSD, Lilly, Pfizer,Celgene, Almirall, Leo Pharma, AbbVie y Amgen., Marta Ferran i Farrés Speakers bureau: Janssen, Lilly, Novartis, Pfizer, MSD, AbbVie, Celgene y Almirall., Paid instructor for: Janssen, Lilly, Novartis, Pfizer, MSD, AbbVie, Celgene y Almirall., Consultant of: Janssen, Lilly, Novartis, Pfizer, MSD, AbbVie, Celgene y Almirall., Raquel Rivera Díaz Speakers bureau: AbbVie, Almirall, Celgene Corporation, GSK, Janssen-Cilag, Lilly, LEO Pharma, MSD, Novartis, Pfizer y UCB., Paid instructor for: AbbVie, Almirall, Celgene Corporation, GSK, Janssen-Cilag, Lilly, LEO Pharma, MSD, Novartis, Pfizer y UCB., Consultant of: AbbVie, Almirall, Celgene Corporation, GSK, Janssen-Cilag, Lilly, LEO Pharma, MSD, Novartis, Pfizer y UCB., David Vidal Sarro Speakers bureau: Lilly, Janssen, AbbVie, Novartis, UCB, Celgene, Gebro y Leo., Paid instructor for: Lilly, Janssen, AbbVie, Novartis, UCB, Celgene, Gebro y Leo., Consultant of: Lilly, Janssen, AbbVie, Novartis, UCB, Celgene, Gebro y Leo., lourdes rodriguez freire Speakers bureau: AbbVie, Janssen Pharmaceuticals Inc., MSD, Pfizer-Wyeth, Novartis, Celgene, Almirall SA, Lilly y Leo-Pharma., Consultant of: AbbVie, Janssen Pharmaceuticals Inc., MSD, Pfizer-Wyeth, Novartis, Celgene, Almirall SA, Lilly y Leo-Pharma., Pablo de la Cueva Dobao Speakers bureau: AbbVie, Almirall, Amgen, Boehringer, Biogen, Celgene, Gebro, Janssen Cilag, Leo-Pharma, Lilly, MSD, Novartis, Pfizer- Wyeth, Sandoz, Sanofi y UCB., Paid instructor for: AbbVie, Almirall, Amgen, Boehringer, Biogen, Celgene, Gebro, Janssen Cilag, Leo-Pharma, Lilly, MSD, Novartis, Pfizer- Wyeth, Sandoz, Sanofi y UCB., Consultant of: AbbVie, Almirall, Amgen, Boehringer, Biogen, Celgene, Gebro, Janssen Cilag, Leo-Pharma, Lilly, MSD, Novartis, Pfizer- Wyeth, Sandoz, Sanofi y UCB., Jorge Santos Juanes Speakers bureau: Novartis, Lilly, Janssen, Abbvie, Amgen, y Sanofi., Consultant of: Novartis, Lilly, Janssen, Abbvie, Amgen, y Sanofi., Grant/research support from: Novartis, Lilly, Janssen, Abbvie, Amgen, y Sanofi., Vicenç Rocamora Duran Speakers bureau: Jansen, Lilly, Abbvie, Almirall, Amgen y Novartis., Paid instructor for: Jansen, Lilly, Abbvie, Almirall, Amgen y Novartis., Cristina Sanabra Employee of: Novartis Pharmaceuticals Spain, Guillermo Guinea Uzábal Employee of: Novartis Pharmaceuticals Spain, Víctor Martín Vázquez Employee of: Novartis Pharmaceuticals Spain
- Published
- 2022
20. Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis
- Author
-
L. Ferrándiz Pulido, R. Rivera Díaz, Ricardo Ruiz-Villaverde, O. Baniandrés Rodríguez, J.A. Martínez-López, M. Velasco, A. Vicente Villa, E. Pérez Pascual, José Manuel Carrascosa, S. Armesto Alonso, A. Pérez Ferriols, Marta García-Bustínduy, N. Martínez Sánchez, Isabel Belinchón, M. Ara-Martín, and R. Taberner Ferrer
- Subjects
Fertility ,Pregnancy ,Postpartum ,RL1-803 ,Breastfeeding ,Psoriasis ,Delphi process ,General Medicine ,Dermatology ,Internal medicine ,RC31-1245 - Abstract
Objetivo Desarrollar recomendaciones basadas en la mejor evidencia y experiencia sobre el manejo de pacientes con psoriasis durante la edad fértil, el embarazo, el posparto y la lactancia. Métodos Se siguió la metodología de grupos nominales y Delphi. Se seleccionó un grupo director de expertos (12 dermatólogos —de los cuales 2 fueron los coordinadores—, 1 reumatólogo, 2 ginecólogos). Se realizó una revisión sistemática de la literatura sobre fertilidad, embarazo, posparto y lactancia en pacientes con psoriasis. Con esta información los coordinadores generaron una serie de recomendaciones preliminares. Todo ello se presentó y discutió con el resto de expertos en una reunión de grupo nominal donde se definió el alcance, los usuarios, los apartados del documento, y donde se generaron las recomendaciones definitivas. El grado de acuerdo con las recomendaciones se votó siguiendo la metodología Delphi, que se extendió a 51 dermatólogos más, según una escala de 1 (total desacuerdo) a 10 (total acuerdo), definiéndose el acuerdo como una puntuación = 7 por al menos el 70% de los participantes. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford. El documento completo final fue aprobado por el panel de expertos. Resultados Se generaron 23 recomendaciones sobre el periodo pre-concepcional (fertilidad y anticoncepción), el embarazo (planificación, manejo farmacológico y seguimiento) y la lactancia (manejo y seguimiento). Todas las recomendaciones menos una alcanzaron el nivel de acuerdo definido. Conclusiones En los pacientes con psoriasis en edad fértil estas recomendaciones pueden mejorar el manejo, los resultados y el pronóstico. Objective To develop evidence- and experience-based recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. Methods The nominal group technique and the Delphi method were used. Fifteen experts (12 dermatologists, 2 of whom were appointed coordinators; 1 rheumatologist; and 2 gynecologists) were selected to form an expert panel. Following a systematic review of the literature on fertility, pregnancy, postpartum, and breastfeeding in women with psoriasis, the coordinators drew up a series of preliminary recommendations for discussion by the panel at a nominal group meeting. The experts defined the scope, sections, and intended users of the statement and prepared a final list of recommendations. Consensus was obtained using a Delphi process in which an additional 51 dermatologists rated their level of agreement with each recommendation on a scale of 1 (total disagreement) to 10 (total agreement). Consensus was defined by a score of 7 or higher assigned by at least 70% of participants. Level of evidence and strength of recommendation were reported using the Oxford Center for Evidence-Based Medicine categories. The final statement was approved by the expert panel. Results The resulting consensus statement includes 23 recommendations on preconception (fertility and contraception), pregnancy (planning, pharmacological management, and follow-up), and breastfeeding (management and follow-up). Consensus was achieved for all recommendations generated except one. Conclusions These recommendations for the better management of psoriasis in women of childbearing age could improve outcomes and prognosis.
- Published
- 2020
21. Descripción de los pacientes que reciben biológicos como primer tratamiento sistémico en el registro BIOBADADERM durante el periodo 2008-2016
- Author
-
F.J. Gómez-García, José L. López-Estebaranz, I. Belinchón Romero, C. Muñoz Santos, R. Rivera Díaz, Mar Llamas-Velasco, G. Carretero Hernández, J.M. Carrascosa Carrillo, E. Daudén Tello, M. Ferrán Farrés, P. de la Cueva-Dobao, J.L. Sánchez-Carazo, M. Alsina Gibert, Enrique Herrera-Ceballos, Ignacio García-Doval, A. González Quesada, M.V. Mendiola Fernández, D.P. Ruiz Genao, Carlos Ferrándiz, and Miguel Ángel Descalzo
- Subjects
030203 arthritis & rheumatology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,General Medicine - Abstract
Resumen Introduccion y objetivos La utilizacion clinica habitual de los farmacos biologicos en el tratamiento de la psoriasis es en segunda linea, es decir, tras el uso previo de un farmaco clasico. Sin embargo, en casos particulares –particularidades del paciente o criterio medico– se realiza la indicacion en primera linea. No existen estudios sobre las caracteristicas demograficas, clinicas y de seguridad de los pacientes que reciben farmaco biologico en primera linea. Como objetivo primario se pretende determinar dichas caracteristicas de acuerdo con la iniciacion de la terapia biologica en primera o segunda linea. Material y metodo Se realizo un estudio descriptivo, multicentrico, de 181 pacientes que iniciaron tratamiento biologico como primer farmaco sistemico para control de su psoriasis moderada-grave, y que forman parte del Registro Espanol de Acontecimientos Adversos Asociados con Medicamentos Biologicos en Dermatologia, entre enero de 2008 y noviembre de 2016. Resultados Los pacientes de ambos grupos son muy similares, si bien se evidencia que el grupo que recibe el biologico en primera linea presenta una edad mas avanzada, sin que se justifique por gravedad de la enfermedad (PASI) ni por el tiempo de evolucion de esta desde el diagnostico. En este grupo de pacientes es mas frecuente la presencia de hipertension, diabetes y hepatopatia. No hemos encontrado diferencias en motivos de suspension ni seguridad entre ambos grupos. Conclusiones No se han encontrado diferencias relevantes entre los 2 grupos, lo cual refuerza la seguridad de los farmacos biologicos en este contexto.
- Published
- 2018
22. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016
- Author
-
I. Belinchón Romero, M. Alsina Gibert, E. Daudén Tello, F.J. Gómez-García, R. Rivera Díaz, Carlos Ferrándiz, Miguel Ángel Descalzo, Ignacio García-Doval, C. Muñoz Santos, Enrique Herrera-Ceballos, A. González Quesada, M.V. Mendiola Fernández, J.L. Sánchez-Carazo, J.M. Carrascosa Carrillo, M. Ferrán Farrés, José L. López-Estebaranz, Mar Llamas-Velasco, G. Carretero Hernández, D.P. Ruiz Genao, and P. de la Cueva-Dobao
- Subjects
030203 arthritis & rheumatology ,Drug ,medicine.medical_specialty ,Histology ,business.industry ,media_common.quotation_subject ,Dermatology ,medicine.disease ,Systemic therapy ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Drug withdrawal ,Liver disease ,0302 clinical medicine ,Internal medicine ,Diabetes mellitus ,Psoriasis ,medicine ,Observational study ,Adverse effect ,business ,media_common - Abstract
Introduction and objectives Biologic drugs are usually prescribed as second-line treatment for psoriasis, that is, after the patient has first been treated with a conventional psoriasis drug. There are, however, cases where, depending on the characteristics of the patient or the judgement of the physician, biologics may be chosen as first-line therapy. No studies to date have analyzed the demographics or clinical characteristics of patients in this setting or the safety profile of the agents used. The main aim of this study was to characterize these aspects of first-line biologic therapy and compare them to those observed for patients receiving biologics as second-line therapy. Material and method We conducted an observational study of 181 patients treated in various centers with a systemic biologic drug as first-line treatment for moderate to severe psoriasis between January 2008 and November 2016. All the patients were registered in the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology. Results The characteristics of the first- and second-line groups were very similar, although the patients receiving a biologic as first-line treatment for their psoriasis were older. No differences were observed for disease severity (assessed using the PASI) or time to diagnosis. Hypertension, diabetes, and liver disease were all more common in the first-line group. There were no differences between the groups in terms of reasons for drug withdrawal or occurrence of adverse effects. Conclusions No major differences were found between patients with psoriasis receiving biologic drugs as first- or second-line therapy, a finding that provides further evidence of the safety of biologic therapy in patients with psoriasis.
- Published
- 2018
23. Acquired Dermal Melanocytosis on the Back of a Patient With Psoriasis
- Author
-
R. Rivera-Díaz, S. Burillo-Martínez, L. Flores, and J.L. Rodríguez Peralto
- Subjects
medicine.medical_specialty ,Histology ,business.industry ,Psoriasis ,medicine ,Dermatology ,medicine.disease ,business ,Pathology and Forensic Medicine - Published
- 2018
24. Melanocitosis dérmica adquirida de la espalda en un paciente con psoriasis
- Author
-
S. Burillo-Martínez, J.L. Rodríguez Peralto, L. Flores, and R. Rivera-Díaz
- Subjects
business.industry ,Medicine ,General Medicine ,business - Published
- 2018
25. Necrobiosis lipoídica: una manifestación más de la diabetes mellitus
- Author
-
M. Puerta-Peña, R. Rivera Díaz, and C. García-Donoso
- Subjects
Public Health, Environmental and Occupational Health ,Family Practice - Published
- 2020
26. Can Psoriasis Produce Irreversible Alopecia?
- Author
-
F. Vanaclocha Sebastian, R. Rivera Díaz, J.L. Rodríguez Peralto, and C. Gutiérrez García-Rodrigo
- Subjects
medicine.medical_specialty ,Histology ,business.industry ,Dermatology ,medicine.disease ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Psoriasis ,medicine ,030211 gastroenterology & hepatology ,Young adult ,business - Published
- 2016
27. ¿La psoriasis produce alopecia irreversible?
- Author
-
C. Gutiérrez García-Rodrigo, J.L. Rodríguez Peralto, R. Rivera Díaz, and F. Vanaclocha Sebastian
- Subjects
030207 dermatology & venereal diseases ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,Medicine ,General Medicine ,business ,Dermatology - Published
- 2016
28. Parafinoma de pene: ¿le hacemos una ecografía?
- Author
-
F. Tous-Romero, Carlos Morales-Raya, R. Rivera-Díaz, and A. Calleja-Algarra
- Subjects
030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,business.industry ,Medicine ,General Medicine ,business ,030218 nuclear medicine & medical imaging - Published
- 2017
29. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016
- Author
-
G, Carretero Hernández, C, Ferrándiz, R, Rivera Díaz, E, Daudén Tello, P, de la Cueva-Dobao, F J, Gómez-García, E, Herrera-Ceballos, I, Belinchón Romero, J L, López-Estebaranz, M, Alsina Gibert, J L, Sánchez-Carazo, M, Ferrán Farrés, A, González Quesada, J M, Carrascosa Carrillo, M, Llamas-Velasco, M V, Mendiola Fernández, D, Ruiz Genao, C, Muñoz Santos, I, García-Doval, and M A, Descalzo
- Subjects
Adult ,Male ,Biological Products ,Drug Substitution ,Tumor Necrosis Factor-alpha ,Antibodies, Monoclonal ,Comorbidity ,Middle Aged ,Drug Utilization ,Age Distribution ,Spain ,Humans ,Psoriasis ,Female ,Registries ,Immunosuppressive Agents ,Aged - Abstract
Biologic drugs are usually prescribed as second-line treatment for psoriasis, that is, after the patient has first been treated with a conventional psoriasis drug. There are, however, cases where, depending on the characteristics of the patient or the judgement of the physician, biologics may be chosen as first-line therapy. No studies to date have analyzed the demographics or clinical characteristics of patients in this setting or the safety profile of the agents used. The main aim of this study was to characterize these aspects of first-line biologic therapy and compare them to those observed for patients receiving biologics as second-line therapy.We conducted an observational study of 181 patients treated in various centers with a systemic biologic drug as first-line treatment for moderate to severe psoriasis between January 2008 and November 2016. All the patients were registered in the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology.The characteristics of the first- and second-line groups were very similar, although the patients receiving a biologic as first-line treatment for their psoriasis were older. No differences were observed for disease severity (assessed using the PASI) or time to diagnosis. Hypertension, diabetes, and liver disease were all more common in the first-line group. There were no differences between the groups in terms of reasons for drug withdrawal or occurrence of adverse effects.No major differences were found between patients with psoriasis receiving biologic drugs as first- or second-line therapy, a finding that provides further evidence of the safety of biologic therapy in patients with psoriasis.
- Published
- 2017
30. Deep Vein Thrombosis in A Patient with Lepromatous Leprosy Receiving Thalidomide to Treat Leprosy Reaction
- Author
-
M. Burgués-Calderón, L. Fuertes, Francisco Vanaclocha, M. Villar-Buill, G. Hebe Petiti-Martin, I. de la Hera, and R. Rivera-Díaz
- Subjects
medicine.medical_specialty ,Lepromatous leprosy ,Histology ,integumentary system ,business.industry ,Deep vein ,Leprostatic agent ,Dermatology ,medicine.disease ,Thrombosis ,Pathology and Forensic Medicine ,Surgery ,Thalidomide ,Venous thrombosis ,medicine.anatomical_structure ,Prednisone ,medicine ,Leprosy ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
- Published
- 2013
31. Trombosis venosa profunda en paciente con lepra lepromatosa tratado con talidomida por leprorreacción
- Author
-
M. Villar-Buill, M. Burgués-Calderón, R. Rivera-Díaz, I. de la Hera, G. Hebe Petiti-Martin, Francisco Vanaclocha, and L. Fuertes
- Subjects
medicine.medical_specialty ,Chemotherapy ,Lepromatous leprosy ,integumentary system ,business.industry ,Deep vein ,medicine.medical_treatment ,General Medicine ,medicine.disease ,Thrombosis ,Dermatology ,Surgery ,Thalidomide ,medicine.anatomical_structure ,Prednisone ,medicine ,Leprosy ,skin and connective tissue diseases ,business ,Complication ,medicine.drug - Abstract
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
- Published
- 2013
32. Penile Paraffinoma: Should We Perform Ultrasound?
- Author
-
Carlos Morales-Raya, Fátima Tous-Romero, Alba Calleja-Algarra, and R. Rivera-Díaz
- Subjects
Adult ,Male ,medicine.medical_specialty ,Histology ,Penile Diseases ,business.industry ,Injections, Subcutaneous ,Ultrasound ,Dermatology ,Cosmetic Techniques ,Plastic Surgery Procedures ,Giant Cells ,030218 nuclear medicine & medical imaging ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Skin Ulcer ,medicine ,Humans ,Mineral Oil ,Radiology ,business ,Ultrasonography - Published
- 2016
33. Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction
- Author
-
G, Hebe Petiti-Martin, M, Villar-Buill, I, de la Hera, L, Fuertes, M, Burgués-Calderón, R, Rivera-Díaz, and F, Vanaclocha
- Subjects
Adult ,Leprosy, Lepromatous ,Male ,Venous Thrombosis ,Humans ,Leprostatic Agents ,Thalidomide - Abstract
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
- Published
- 2011
34. [Lichen planus and hepatitis C virus infection. Study of 6 cases]
- Author
-
F, Revenga Arranz, D, de Argila Fernández-Durán, R, Rivera Díaz, and L, Iglesias Díez
- Subjects
Adult ,Male ,Lichen Planus ,Humans ,Female ,Middle Aged ,Hepatitis C ,Aged - Abstract
Lichen planus is an inflammatory dermatosis that has been associated to different chronic hepatopaties with a variable frequency. In recent years several case reports have been published dealing with lichen planus and its association to hepatitis C virus infection. We report six patients with lichen planus (four males, two females; aged 30-75) who also suffered a chronic hepatitis C virus infection. Lichen planus was confirmed by biopsy and viral infection was based on ELISA and RIBA-4 tests in all patients and also on PCR in five of them. A patient had also been diagnosed of porphyria cutanea tarda. Two patients were treated with alfa-Interferon. It did not modify the evolution of their lichen planus. We recommend to search for hepatitis C virus infection in lichen planus patients and also look for lichen planus patients suffering of chronic hepatopathies to improve our knowledge of the possible relation between both diseases.
- Published
- 1995
35. [Polymicrobial endocarditis: presentation of 3 cases]
- Author
-
C, Díaz Pedroche, J, González Castelló, A, Coto López, C, González Gómez, R, Rivera Díaz, S, Sancho García, and C, Fernández-Miranda
- Subjects
Adult ,Male ,Catheters, Indwelling ,Humans ,Female ,Endocarditis, Bacterial ,Middle Aged ,Substance Abuse, Intravenous - Abstract
We present three cases of polymicrobian endocarditis (PE), two of them in parenterally drug addicts (PDA) and the other one in a central catheter carrier. In all these three cases, the form of clinical presentation was similar to the monomicrobian endocarditis and the valve affected was the tricuspid one, as it occurs in most of the described PE. PE must be suspect in PDA or central catheter carriers if a rare germ is isolated (commensal of skin, oropharynx or gastrointestinal tract) or if there is a poor response to the antibiotic treatment, as it is the case in the patients described here.
- Published
- 1994
36. Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series.
- Author
-
Carlos CA, Tous-Romero F, García-Donoso C, Puig-Buendia J, Borja GR, Cavestany-Rodríguez R, and Rivera-Díaz R
- Published
- 2024
- Full Text
- View/download PDF
37. Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients.
- Author
-
Montero-Menárguez J, Amat Samaranch V, Puig Sanz L, Ruiz-Villaverde R, Arias-Santiago S, Larrea García M, Ruiz Genao D, Ferrán M, Schneller-Pavelescu L, Romero Ferreiro C, and Rivera Díaz R
- Subjects
- Humans, Male, Retrospective Studies, Female, Middle Aged, Spain epidemiology, Aged, Adult, Child, Adolescent, Child, Preschool, Young Adult, Aged, 80 and over, Dermatitis, Exfoliative etiology, Dermatitis, Exfoliative pathology, Treatment Outcome, Adrenal Cortex Hormones therapeutic use, Infant, Pityriasis Rubra Pilaris pathology, Pityriasis Rubra Pilaris drug therapy
- Abstract
Introduction: PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians., Objective: To add our experience to increase evidence about PRP., Methods: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP., Results: PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response., Conclusion: Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma., (Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. [Translated article] Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts.
- Author
-
Rivera-Díaz R, Carrascosa Carrillo JM, Alfonso Zamora S, Navarro Valdivieso JP, Muñoz Cabello B, Ros Abarca S, Soria de Francisco JM, and Daudén Tello E
- Subjects
- Humans, Spain, Disease Progression, Disease Management, Practice Guidelines as Topic, Quality Improvement, Consensus, Psoriasis therapy, Psoriasis drug therapy
- Abstract
This consensus document analyzed the management and emotional journey of patients with GPP (generalized pustular psoriasis), and the desirable course of the disease while detecting critical points and translating them into needs and recommendations. This project was conducted in 3 phases with participation from an advisory committee (n=8), an expert panel (n=15) and patients with GPP (n=6). The patients' disease progression was heterogeneous due to disease variations, different health care models implemented and available resources, and the lack of diagnostic and treatment guidelines. A total of 45 different recommendations have been made to optimize management and address the emotional component of these patients. Five of them stand out for their impact and viability. Therefore, a roadmap of priorities has been made generally available to improve the management of patients with GPP., (Copyright © 2024. Publicado por Elsevier España, S.L.U.)
- Published
- 2024
- Full Text
- View/download PDF
39. Clinical characteristics and risk factors for secondary lymphoedema in hidradenitis suppurativa.
- Author
-
Garbayo-Salmons P, Lara-Moya A, Haselgruber S, Vilarrasa E, Martorell A, Gamissans M, Gracia-Darder I, Aguayo-Ortiz RS, Ciudad C, Rivera-Díaz R, Mora-Fernandez V, Romaní J, Garcias-Ladaria J, Fornons-Servent R, Bailón DF, and Molina-Leyva A
- Published
- 2024
- Full Text
- View/download PDF
40. Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial.
- Author
-
López Ferrer A, Belinchón Romero I, Rivera Díaz R, and Herranz Pinto P
- Published
- 2024
- Full Text
- View/download PDF
41. A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study.
- Author
-
Puig L, Izu Belloso R, Rivera-Díaz R, Mollet Sánchez J, Rodríguez Fernández-Freire L, Sahuquillo-Torralba A, and Ruiz-Villaverde R
- Abstract
Introduction: Generalized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening skin condition characterized by flares comprising widespread sterile pustules and systemic inflammation. Both the rarity and heterogeneity of the disease have made GPP classification and standardization of clinical criteria challenging. Before the approval of spesolimab (IL-36R antibody) in 2022, there were no approved treatments in the USA or Europe for GPP flares. Treatment for GPP has amounted to off-label use of medicines approved to treat plaque psoriasis. Our aim was to describe the sociodemographics, clinical characteristics, and treatment patterns of patients with GPP in Spain., Methods: Non-interventional, descriptive, multi-center, retrospective chart review of patients diagnosed with GPP in Spain., Results: 56 patients (50% women) were included, with a mean (standard deviation, SD) age at diagnosis of 53.7 (20.5) and a mean (SD) time of follow-up of 3.7 (3.1) years. In 80% of patients, GPP diagnosis was associated with a flare and 67.3% had known risk factors for GPP (such as previous diagnosis or family history of plaque psoriasis, comorbidities, smoking or stress). Hypertension and plaque psoriasis were the most frequent comorbidities (44.6% each). The number of GPP flares per patient-year was 0.55 with (range 0-4) a mean (SD) body surface area involvement of 21.3% (19.1). The most frequent manifestations of GPP flares were pustules (88.5%), erythema (76.9%), and scaling (76.9%). Additionally, 65.4% of patients had plaque psoriasis, 53.8% had unspecified skin lesions, and 30.8% experienced pain. The treatments used for GPP flares were off-label conventional systemic drugs (75%), mostly corticosteroids, cyclosporine, and acitretin. In the periods between flares, off-label biologics were used in 56.5% of patients. During the study period, 9 patients (16.1%) had at least one complication and 5 of them required hospitalization., Conclusion: This is the first multicenter study in Spanish GPP patients. Most patients were in their fifties, with personal or family history of plaque psoriasis, stress, smoking and a wide range of comorbidities and complications. Even though the number of flares per patient/year was 0.55, there was variability between patients. Both off-label conventional systemics and off-label biologics were used for flare management without a clear treatment pattern., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
42. [Translated article] Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients.
- Author
-
Belinchón-Romero I, López-Ferrer A, Ferrán I Farrés M, Rivera-Díaz R, Vidal-Sarro D, Rodríguez Fernández-Freire L, de la Cueva-Dobao P, Santos-Juanes J, Rocamora-Durán V, Martín-Vázquez V, Gómez-Labradror L, and Queiro-Silva R
- Subjects
- Humans, Female, Cross-Sectional Studies, Male, Middle Aged, Adult, Surveys and Questionnaires, Reproducibility of Results, Translations, Sensitivity and Specificity, Spain, Feasibility Studies, Language, Arthritis, Psoriatic diagnosis, Early Diagnosis, Psoriasis diagnosis
- Abstract
Background and Objective: Psoriasis often precedes the onset of psoriatic arthritis (PsA), so dermatologists often face the challenge of early identifying signs of PsA in patients with psoriasis. Our aim was to validate the Spanish version of the PURE-4 questionnaire as a screening tool for PsA, evaluate its performance in terms of sensitivity, specificity, feasibility, reliability, and build validity., Methods: This was a cross-sectional, observational, multicenter trial of adult patients with psoriasis. Initially, patients were assessed by a dermatologist and completed 2 self-administered versions (in print and online) of the PURE-4 questionnaire. Afterwards, the rheumatologist, blinded to the PURE-4 results, assessed the presence/absence of PsA, being the reference to determine the performance of the PURE-4 questionnaire., Results: A total of 268 patients were included (115 [42.9%] women; mean age, 47.1±12.6). The prevalence of PsA according to rheumatologist diagnosis was 12.7% (34 patients). The mean PURE-4 score for patients with psoriasis diagnosed with PsA was 2.3±1.1, and 1.3±1.3 for patients without PsA (P<.001). The cutoff value ≥2 demonstrated the best performance for detecting PsA, with a negative predictive value of 95.1% (95% confidence interval, 90.3-97.6)., Conclusions: The PURE-4 questionnaire demonstrated good performance in detecting PsA, with an optimal cutoff point ≥2. This simple tool could facilitate early referral of patients to the rheumatology unit., (Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
- Author
-
Martorell A, Santos-Alarcón S, Sahuquillo-Torralba A, Rivera-Díaz R, Belinchón-Romero I, Ruiz-Genao D, Romero-Maté A, Ruiz-Villaverde R, Ferran-Farrés M, Gallardo-Hernández F, Almenara-Blasco M, Suarez-Perez JA, González-Cantero Á, Martínez-Lorenzo E, Fernández-Armenteros JM, Del Alcázar-Viladomiu E, García-Latasa J, Rocamora-Durant V, Ara-Martín M, Mateu-Puchades A, Llamas-Velasco M, Vilarrasa E, Velasco-Pastor M, De la Cueva P, Carrascosa JM, and Magdaleno-Tapial J
- Abstract
Background and Objective: Risankizumab - a humanized monoclonal antibody that targets the p19 subunit of IL-23 - has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking., Objective: To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice., Methods: This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52., Results: A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7±14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] >30kg/m
2 ). The mean baseline PASI score was 11.4±7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI ≤2 was greater in the group with a BMI ≤30kg/m2 on weeks 4 (P=.04), 16 (P=.001), and 52 (P=.002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (P=.001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (P=.04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment., Conclusions: Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice., (Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
44. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
- Author
-
Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, Rivera-Díaz R, Sahuquillo-Torralba A, Llamas-Velasco M, Gómez-García FJ, Herrera-Acosta E, de la Cueva P, Baniandrés-Rodríguez O, Lopez-Estebaranz JL, Belinchón I, Ferrán M, Mateu A, Rodríguez L, Riera-Monroig J, Abalde-Pintos MT, Carretero G, García-Donoso C, Pujol-Marco C, Del Alcázar E, Santamaría-Domínguez C, Suárez-Pérez JA, Nieto-Benito LM, Ruiz-Genao DP, Salgado-Boquete L, Descalzo MÁ, and García-Doval I
- Subjects
- Humans, Methotrexate, Cohort Studies, Registries, Biological Therapy, Psoriasis pathology, Biological Products adverse effects
- Abstract
Background: Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety is the main purpose of the BIOBADADERM registry. The combination of a biologic agent and a conventional systemic drug [generally methotrexate (MTX)] is a common treatment in clinical practice. However, there is a paucity of evidence from real-world practice on the safety of such combination regimens in the treatment of psoriasis., Objectives: The primary objective of this study was to ascertain whether the use of regimens combining biologic drugs with MTX in the management of moderate-to-severe psoriasis increases the risk of adverse events (AEs) or serious AEs (SAEs). We compared monotherapy using tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors with the use of the same drugs in combination with MTX., Methods: Using data from the BIOBADADERM registry, we compared biologic monotherapies with therapies that were combined with MTX. We estimated adjusted incidence rate ratios (aIRR) using a random effects Poisson regression with 95% confidence intervals for all AEs, SAEs, infections and serious infections and other AEs by system organ class., Results: We analysed data from 2829 patients and 5441 treatment cycles, a total of 12 853 patient-years. The combination of a biologic with MTX was not associated with statistically significant increases in overall risk of AEs or SAEs in any treatment group. No increase in the total number of infections or serious infections in patients receiving combined therapy was observed for any group. However, treatment with a TNF inhibitor combined with MTX was associated with an increase in the incidence of gastrointestinal AEs (aIRR 2.50, 95% CI 1.57-3.98; P < 0.002)., Conclusions: The risk of AEs and SAEs was not significantly increased in patients with moderate-to-severe psoriasis receiving different classes of biologic drugs combined with MTX compared with those on biologic monotherapy., Competing Interests: Conflicts of interest J.M.C. has participated as a speaker and/or advisor and/or principal investigator/senior investigator in clinical trials sponsored by for Celgene, Janssen, Lilly, Leo Pharma, Novartis, Pfizer, MSD, Biogen, Mylan, Amgen, AbbVie and Sandoz. A.G.-Q. acted as consultant and/or speaker for and/or participated in clinical trials as principal investigator and subinvestiator for AbbVie, Almirall, Amgen, Boehringer, Janssen, Leo Pharma, Lilly, Novartis, MSD, Pfizer-Wyeth and UCB. R.R.-D. acted as consultant and/or speaker for and/or participated in clinical trials as principal investigator for AbbVie, Almirall, Amgen, Boehringer, Janssen, Leo Pharma, Lilly, Novartis, MSD, Pfizer-Wyeth and UCB. A.S.-T. has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis and Pfizer. M.L.-V. acted as a consultant and speaker and participated in clinical trials for Janssen-Cilag, AbbVie, Boehringer, Celgene, Pfizer, Novartis, Lilly, Almirall, UCB, Kyowa Kirin and Leo Pharma. E.H.-A. has served as consultant and/or speaker with Leo Pharma, Novartis, Janssen, Lilly, Celgene and AbbVie. P.d.l.C. acted as a consultant and/or speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, UCB, Biogen, Celgene, Amgen, Sandoz, Sanofi and Leo Pharma. O.B.-R. acted as a consultant and/or speaker for Janssen-Cilag, AbbVie, Pfizer, Novartis, Lilly, Celgene, Leo Pharma, Amgen, Boehringer, UCB and Almirall. L.L.-E. participated as advisory board member and received educational grants from Janssen, AbbVie, MSD, Lilly, Novartis, LeoPharma and Pfizer. I.B. acted as a consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc., Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen Amgen, Leo Pharma, UCB, Pfizer-Wyeth and MSD. M.F. has participated as speaker and/or advisor for Janssen, Lilly, Novartis, Pfizer, MSD, AbbVie Celgene and Almirall. A.M. acted as consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, Leo Pharma, Lilly, Novartis. L.R. acted as a consultant and speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, Celgene and Leo Pharma. J.R.-M. acted as a consultant and/or speaker for and/or participated in clinical trials sponsored by AbbVie, Almirall, Janssen, Leo Pharma, Novartis, UCB, Pfizer, Lilly, Amgen and Boehringer Ingelheim. G.C. has been reimbursed by Janssen, AbbVie, Novartis, Pfizer, MSD and Celgene for advisory service and conference attendance. C.G.-D. participated as advisory board member for AbbVie, Almirall and speaker for Janssen, Lilly and Celgene. C.P.-M. acted as a consultant and/or speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, UCB, Celgene and Leo Pharma. E.D.A. has participated as a speaker and/or and/or PI/SI clinical trials sponsored by Amgen, Almirall, Janssen, Lilly, Leo Pharma, Novartis, UCB and AbbVie. J.A.S.-P. has served as consultant and/or speaker with Leo Pharma, Novartis, Janssen, Lilly, Celgene, AbbVie, Amgen, Sanofi, Almirall and Pfizer. D.P.R.-G. has been reimbursed by Pfizer, Janssen, Celgene, AbbVie, Novartis and LeoPharma for advisory services and conference attendance. I.G.D. received travel grants for congresses from AbbVie, MSD, Pfizer and Sanofi., (© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
45. Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study.
- Author
-
Jiménez Gómez N, González-Cantero Á, Ruiz-Villaverde R, Llamas-Velasco M, de la Cueva Dobao P, Rivera Díaz R, Martínez Lorenzo E, Alonso Pacheco ML, Baniandrés Rodríguez O, Mollet Sánchez J, Pitarch Bort G, Izu Belloso RM, and Jaén Olasolo P
- Subjects
- Humans, Female, Pregnancy, Adult, Cross-Sectional Studies, Quality of Life, Surveys and Questionnaires, Family Planning Services, Psoriasis drug therapy
- Abstract
Background and Objective: A significant proportion of women of childbearing age have psoriasis. The aim of this study was to examine family planning concerns in this population., Material and Methods: Observational, descriptive, cross-sectional, multicenter study conducted between March 2020 and October 2021. We collected sociodemographic data and analyzed responses to a family planning questionnaire administered to women aged 18 to 45 years with plaque psoriasis who were candidates for systemic treatment., Results: We studied 153 patients (mean [SD] age, 35.4 [8.0] years; mean disease duration, 16.7 years) being treated at 11 Spanish hospitals. Overall, 38.4% of women were considered to have moderate to severe psoriasis by their physicians; perceived severity ratings were significantly higher among women. Psoriasis affected the women's desire to become pregnant or led to their delaying pregnancy in 1 in 3 respondents. They were concerned that their condition might worsen if they had to discontinue or switch treatment or that the treatment might harm the baby. Approximately half of the women had not received family planning counseling from their physicians, and this was more likely to be the case among never-pregnant women. Women on biologic therapy (58.7%) had better psoriasis control and a better quality of life than women on other treatments. Their sexual health was also less affected., Conclusions: Women with psoriasis have numerous family planning concerns, which in some cases can lead them to delay pregnancy or affect their desire to become pregnant. Dermatologists need to receive better training regarding family planning in women with psoriasis so that they can provide their patients with more and better information., (Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study.
- Author
-
Salgado-Boquete L, Arias-Santiago S, Belinchón-Romero I, de la Cuadra-Grande A, de la Cueva P, Gilaberte Y, Notario J, Rivera-Díaz R, Ruiz-Villaverde R, and Carrascosa JM
- Subjects
- Humans, Delphi Technique, Quality Indicators, Health Care, Psoriasis therapy
- Abstract
Defining quality indicators is a key strategy for ensuring the quality and standardization of health care. The CUDERMA project, an initiative of the Spanish Academy of Dermatology and Venerology (AEDV), was undertaken to define quality indicators for the certification of specialized units in dermatology; the first 2 areas selected were psoriasis and dermato-oncology. The aim of this study was to reach a consensus on what should be assessed by the indicators used to certify psoriasis units. The structured process used to do this comprised a literature review to identify potential indicators, the selection of an initial set of indicators to be evaluated by a multidisciplinary group of experts and, finally, a Delphi consensus study. A panel of 39 dermatologists evaluated the selected indicators and classified them as either "essential" or "of excellence". Consensus was finally reached on 67 indicators, which will be standardized and used to develop the certification standard for psoriasis units., (Copyright © 2023. Publicado por Elsevier España, S.L.U.)
- Published
- 2023
- Full Text
- View/download PDF
47. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
- Author
-
Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad Blanco C, Romaní J, Martorell A, Fernández P, Romero Ferreiro C, and Molina Leyva A
- Subjects
- Adult, Humans, Adalimumab therapeutic use, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Biological Products therapeutic use, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa diagnosis, Hidradenitis Suppurativa pathology
- Abstract
Background: Hidradenitis suppurativa (HS) is a chronic skin condition causing lesions in which high levels of interleukin (IL)-23 and T-helper17 cells are found. Adalimumab remains the only approved treatment. Guselkumab, an antibody targeting the p19 protein subunit of extracellular IL-23, is approved for the treatment of moderate-severe psoriasis, but evidence on its efficacy in treating HS is limited., Objectives: To assess the effectiveness and safety of guselkumab in treating moderate-severe HS under clinical practice conditions., Methods: A multicentre retrospective observational study was carried out in 13 Spanish hospitals including adult HS patients treated with guselkumab within a compassionate use programme (March 2020-March 2022). Data referred to patient demographic and clinical characteristics at treatment initiation (baseline), patient-reported outcomes (Numerical Pain Rating Scale [NPRS] and Dermatology Life Quality Index [DLQI]), physician scores (International Hidradenitis Suppurativa Severity Score System [IHS4], HS Physical Global Score [HS-PGA] and Hidradenitis Suppurativa Clinical Response [HiSCR]) were recorded at baseline and at 16, 24, and 48weeks of treatment., Results: A total of 69 patients were included. Most (84.10%) had severe HS (HurleyIII) and had been diagnosed for over ten years (58.80%). The patients had been subjected to multiple non-biological (mean: 3.56) or biological (mean: 1.78) therapies, and almost 90% of those treated with biologics had received adalimumab. A significant decrease in IHS4, HS-PGA, NPRS, and DLQI scores was observed from baseline to 48weeks of guselkumab treatment (all P<.01). HiSCR was achieved in 58.33% and 56.52% of the patients at 16 and 24weeks, respectively. Overall, 16 patients discontinued treatment, mostly due to inefficacy (n=7) or loss of efficacy (n=3). No serious adverse events were observed., Conclusions: Our results indicate that guselkumab may be a safe and effective therapeutic alternative for patients with severe HS that fail to respond to other biologics., (Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
48. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.
- Author
-
Phan DB, Jourdain H, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralba A, Descalzo-Gallego MA, Lunt M, Garcia-Doval I, Sbidian E, Warren RB, and Yiu ZZN
- Subjects
- Humans, Adalimumab therapeutic use, Cohort Studies, Treatment Outcome, Biosimilar Pharmaceuticals adverse effects, Psoriasis drug therapy, Dermatitis
- Abstract
Introduction: Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has reduced the unit cost of treatment. However, the long-term effectiveness and safety of adalimumab biosimilars for treating psoriasis in real-world settings are uncertain and may be a barrier to widespread usage., Methods and Analysis: This study aims to compare the drug survival and safety of adalimumab biosimilars to adalimumab originator for the treatment of psoriasis. We will use both routinely collected healthcare databases and dedicated pharmacovigilance registries from the PsoNet initiative, including data from the UK, France and Spain. We will conduct a cohort study using a prevalent new user design. We will match patients on previous adalimumab exposure time to create two equal-sized cohorts of biosimilar and originator users. The coprimary outcomes are drug survival, defined by the time from cohort entry to discontinuation of the drug of interest; and risk of serious adverse events, defined by adverse events leading to hospitalisation or death. Cox proportional hazards models will be fitted to calculate HRs as the effect estimate for the outcomes., Ethics and Dissemination: The participating registries agree with the Declaration of Helsinki and received approval from local ethics committees. The results of the study will be published in scientific journals and presented at international dermatology conferences by the end of 2023., Competing Interests: Competing interests: RBW reported receiving research grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, Leo, Novartis, Pfizer & UCB; and consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GSK, Janssen, Lilly, Leo, Novartis, Pfizer, Sanofi, Sun Pharma, UCB & UNION. AG-Q acted as consultant and/or speaker for and/or participated in clinical trials for Abbvie, Pfizer, Novartis, Sanofi, Boeringher, Bristol-Meyer, Leo Pharma y Jansen. RR-D acted as consultant and/or speaker for and/or participated in clinical trials as IP for Abbvie, Almirall, Celgene, Janssen, Leo Pharma, Lilly, Novartis, MSD and Pfizer-Wyeth. AS-T has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis and Pfizer. IG-D received travel grants for congresses from Abbvie, MSD and Pfizer., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
49. NanoString analysis of mycosis fungoides reveals individual molecular identity.
- Author
-
Alonso-Alonso R, Rodríguez M, García-Díaz N, Tomás-Roca L, Borregón J, Cabezuelo-Rodríguez M, Rebollo-González M, Gallego-Manzano L, Cereceda L, Rodriguez-Pinilla SM, Córdoba R, Fernando García J, Torre-Castro J, García-Álvarez CM, Del Mar Onteniente Gomis M, Rivera-Díaz R, Rodriguez-Peralto JL, Vaqué JP, Ortiz-Romero PL, and Piris MÁ
- Subjects
- Humans, Mycosis Fungoides diagnosis, Mycosis Fungoides genetics, Skin Neoplasms genetics
- Abstract
Competing Interests: Conflicts of interest M.A.P. declares having received lecture fees and advisory board fees from Celgene, Gilead, Jansen, Kyowa Kirin, Millenium/Takeda and NanoString. P.L.O.-R. declares having received advisory fees from 4SC, Helsinn, Innate Pharma, Kyowa Kirin, Mallinckrodt, Recordati Rare Diseases and Takeda. The authors declare that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
- Published
- 2023
- Full Text
- View/download PDF
50. Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience.
- Author
-
Arroyo-Andrés J, Falkenhain-López D, Agud-Dios M, and Rivera-Díaz R
- Subjects
- Humans, Retrospective Studies, Interleukin-23 therapeutic use, Treatment Outcome, Severity of Illness Index, Arthritis, Psoriatic drug therapy, Psoriasis drug therapy, Biological Products adverse effects, Antirheumatic Agents therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.